Comparison of dose-dense ABVD and standard ABVD in the treatment of early unfavorable and advanced Hodgkin's lymphoma: a retrospective analysis.
This retrospective analysis compared standard regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with the dose-dense ABVD regimen (ABVD-21) in terms of efficacy and toxicity. Patients who had early-stage unfavorable or advanced Hodgkin's lymphoma (HL) according to German Hodgkin Study Group criteria from March 1999 to February 2011 were analyzed for treatment response, long-term survival and hematological toxicity. There were 85 patients in the ABVD-21 group and 118 patients in the ABVD group respectively. The complete remission rates after completion of treatment were 92.9% and 90.7% for ABVD-21 and ABVD, respectively. During a median follow-up period of 62 months, no significant difference was found in projected 10-year progression-free survival (PFS) and overall survival (OS) rates (84.7% and 94.1% respectively for ABVD-21; 81.4% and 91.5% for ABVD). Subgroup analyses showed that ABVD-21 was significantly better than ABVD for patients with IPS≥3 in terms of PFS and OS rates. Grade 3 to 4 leukopenia (51.8% vs. 28.8%, P=0.001) and neutropenia (57.6% vs. 39.0%, P=0.009) were more common with ABVD-21. We were led to conclude that dose-dense ABVD did not result in better tumor control and overall survival than did ABVD for early-stage unfavorable HL. However, patients at high risk, for example, with IPS≥3, may benefit from dose-dense ABVD.
Department of Medical Oncology, Central Hospital of Xuzhou, Xuzhou, 221009, China.
Yun-Xia
YX
Tao
Department of Medical Oncology, Central Hospital of Xuzhou, Xuzhou, 221009, China.
San-Yuan
SY
Sun
Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
Su-Yi
SY
Kang
Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China. zhouliqiang_bj@163.com.
Li-Qiang
LQ
Zhou
Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
Yuan-Kai
YK
Shi
Department of Radiotherapy, Cancer Hospital and Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
Ye-Xiong
YX
Li
Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
Yan
Y
Sun
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy / Q000379:methods*; D003606:Dacarbazine / Q000008:administration & dosage; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone; D012189:Retrospective Studies; D014747:Vinblastine / Q000008:administration & dosage
D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D011241:Prednisone